凸显百悦泽®联合或不联合维奈克拉用于慢性淋巴细胞白血病患者一线治疗的差异化特性SEQUOIA研究D组中,百悦泽®联合维奈克拉用于治疗各类CLL患者(包括伴有del(17p)高危突变患者)均展现出高缓解率和良好的安全性特征SEQUOIA研究C组五年随访数据显示,与历史数据相比,百悦泽®单药用于治疗难以治疗的del(17p)突变CLL患者展现出持续总生存期及无进展生存期获益美国加州圣卡洛斯——百济神州...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.